Lester David S
Theranos, Inc., 3200 Hillview Ave., Palo Alto, CA 94304, USA.
Per Med. 2009 Sep;6(5):555-565. doi: 10.2217/pme.09.31.
Personalized medicine is recognized as being a significant part of the solution for providing better healthcare outcomes. However, there are multiple challenges to its adoption from many healthcare stakeholders. The challenges are not technological, but rather involve the development of the appropriate business model, such that all stakeholders can have the necessary incentives to justify adoption. From a commercial perspective, two different industries with distinct business models are involved: pharma and the diagnostics industry. In order for personalized medicine to have its desired impact, it is necessary that innovative business models from various sectors within healthcare are developed. The problem is that different stakeholders have different motivations, but it is all ultimately driven by economic decisions, and empowering of the patient/consumer will also be a significant factor.
个性化医疗被认为是改善医疗保健效果解决方案的重要组成部分。然而，众多医疗保健利益相关者在采用它时面临多重挑战。这些挑战并非技术层面的，而是涉及到合适商业模式的开发，以便所有利益相关者都能有必要的激励措施来证明采用的合理性。从商业角度来看，涉及到两种具有不同商业模式的不同行业：制药业和诊断行业。为了使个性化医疗产生预期影响，有必要开发医疗保健领域内各部门的创新商业模式。问题在于不同的利益相关者有不同的动机，但这一切最终都由经济决策驱动，而且赋予患者/消费者权力也将是一个重要因素。
